Eggshell membrane as promising supplement to maintain bone health: A systematic review.

Bone density Bone mineralization Collagen type I Glycosaminoglycans

Journal

Bone reports
ISSN: 2352-1872
Titre abrégé: Bone Rep
Pays: United States
ID NLM: 101646176

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 05 02 2024
revised: 14 05 2024
accepted: 21 05 2024
medline: 14 6 2024
pubmed: 14 6 2024
entrez: 14 6 2024
Statut: epublish

Résumé

Bone loss is a well-known phenomenon in the older population leading to increased bone fracture risk, morbidity, and mortality. Supplementation of eggshell membrane (ESM) is evaluated due to its possible application to prevent bone loss and usage in osteoporosis therapy. The similar organic chemical composition of ESM and human bone is described in detail as both mainly consist of collagen type I, chondroitin sulfate, dermatan sulfate, hyaluronic acid and elastan. ESM and its components are reported to improve mineralization in bone tissue. In many studies ESM intake reduced pain in patients with joint disorders and reduced inflammatory processes. Additionally, ESM improved calcium uptake in human cells. These findings in comparison with a clinical pilot study reporting pain reduction in osteoporotic patients and increased osteoblast activity in in vitro assays support ESM to be a beneficial supplement for bone health. In this systematic review we combined chemical structure analysis with clinical studies to give a more comprehensive picture with novel explanations.

Identifiants

pubmed: 38872992
doi: 10.1016/j.bonr.2024.101776
pii: S2352-1872(24)00043-3
pmc: PMC11170356
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

101776

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

JPF reported receiving personal fees from Apomedica Pharmazeutische Produkte GmbH as employee.The authors have no conflict of interest to declare.

Auteurs

Johannes-Paul Fladerer (JP)

Institute of Pharmaceutical Sciences, University of Graz, Beethovenstraße 8, 8010 Graz, Austria.
Apomedica Pharmazeutische Produkte GmbH, Roseggerkai 3, 8010 Graz, Austria.

Selina Grollitsch (S)

Institute of Pharmaceutical Sciences, University of Graz, Beethovenstraße 8, 8010 Graz, Austria.

Classifications MeSH